{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:29:17Z","timestamp":1793104157800,"version":"4.5.0"},"reference-count":91,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2022,8,13]]},"DOI":"10.1080\/14656566.2022.2112945","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T04:36:22Z","timestamp":1660538182000},"page":"1363-1370","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Colesevelam \u2013 a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia"],"prefix":"10.1080","volume":"23","author":[{"given":"Oluwayemisi","family":"Esan","sequence":"first","affiliation":[{"name":"Guy\u2019s & St Thomas Hospitals","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adie","family":"Viljoen","sequence":"additional","affiliation":[{"name":"East & North Hertfordshire Hospitals, Lister Hospital","place":["Stevenage, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Wierzbicki","sequence":"additional","affiliation":[{"name":"Guy\u2019s & St Thomas Hospitals","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1619"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.041998"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dbi19-0007"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/17460875.3.3.237"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.03.056"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30388-2"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.2.187"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_3_3_13_1","first-page":"204748731876661","article-title":"A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes","author":"Khan SU","year":"2018","unstructured":"Khan SU, Talluri S, Riaz H, et al. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. Eur J Preventive Cardiol. 2018 Jan 1:2047487318766612.","journal-title":"Eur J Preventive Cardiol"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03340270029025"},{"issue":"1","key":"e_1_3_3_15_1","first-page":"62","article-title":"Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus","volume":"40","author":"Brunetti L","year":"2015","unstructured":"Brunetti L, DeSantis EH. Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus. P T. 2015 Jan;40(1):62\u201367. .","journal-title":"P T"},{"issue":"3","key":"e_1_3_3_16_1","first-page":"257","article-title":"Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review","volume":"99","author":"Insull W","year":"2006","unstructured":"Insull WsJr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. SouthMedJ. 2006 3;99(3):257\u2013273.","journal-title":"SouthMedJ"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010004"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S26725"},{"issue":"7","key":"e_1_3_3_19_1","first-page":"1232","article-title":"Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia","volume":"50","author":"Donovan JM","year":"2005","unstructured":"Donovan JM, Von BK, Setchell KD, et al. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. DigDisSci. 2005 7;50(7):1232\u20131238.","journal-title":"DigDisSci"},{"issue":"6","key":"e_1_3_3_20_1","first-page":"479","article-title":"GT 31104, CholestaGel","volume":"1","author":"Colesevelam","year":"1999","unstructured":"Colesevelam. GT 31104, CholestaGel. Drugs RD. 1999 6;1(6):479\u2013480.","journal-title":"Drugs RD"},{"issue":"1","key":"e_1_3_3_21_1","first-page":"708","article-title":"Invitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants","volume":"41","author":"Braunlin W","year":"2000","unstructured":"Braunlin W, Zhorov E, Smisek D, et al. Invitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polym Preprints. 2000;41(1):708\u2013709.","journal-title":"Polym Preprints"},{"issue":"5","key":"e_1_3_3_22_1","first-page":"779","article-title":"Colesevelam HCl: a non-systemic lipid-altering drug","volume":"4","author":"Bays H","year":"2003","unstructured":"Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. ExpertOpinPharmacother. 2003 5;4(5):779\u2013790. .","journal-title":"ExpertOpinPharmacother"},{"issue":"7","key":"e_1_3_3_23_1","first-page":"898","article-title":"Colesevelam hydrochloride: a novel bile acid-binding resin","volume":"35","author":"Aldridge MA","year":"2001","unstructured":"Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. AnnPharmacother. 2001 7;35(7\u20138):898\u2013907.","journal-title":"AnnPharmacother"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1985.tb02855.x"},{"issue":"6","key":"e_1_3_3_25_1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1023\/A:1007831418308","article-title":"Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent","volume":"14","author":"Donovan JM","year":"2000","unstructured":"Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. CardiovascDrugs Ther. 2000 12;14(6):681\u2013690.","journal-title":"CardiovascDrugs Ther"},{"key":"e_1_3_3_26_1","unstructured":"British National Formulary. Colesevelam hydrochloride London United Kingdom: National Institute for Helath and Clinical Excellence; 2022. [cited 2022 Jan 6]. Available from: https:\/\/bnf.nice.org.uk\/drugs\/colesevelam-hydrochloride\/"},{"key":"e_1_3_3_27_1","unstructured":"Canadian Drug Expert Committee (CDEC). Common drug review: final CDEC recommendation: colesevelam hydrochloride (Lodalis \u2013 valeant Canada LP) Ottawa: Canada: Canadian Agency for Drugs and Technologies in Health; 2012 [updated 19 Dec 2012; cited 2022 Jan 19]. Final CDEC Recommendation - Lodalis - CADTH Available from: https:\/\/www.cadth.ca\u203adefault\u203afiles\u203acdr\u203acomplete"},{"key":"e_1_3_3_28_1","unstructured":"Galescu OA. Clinical review NDA 210895 Welchol (colesevelam hydrochloride) Washington DC USA: food and drug administration. 2017. [updated 08 Aug 2018; cited 2022 Jan 6]. Clinical Review Ovidiu A. Galescu MD NDA 210895 Welchol Available from: https:\/\/www.fda.gov\u203amedia\u203adownload"},{"issue":"16","key":"e_1_3_3_29_1","first-page":"1893","article-title":"Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects","volume":"159","author":"Davidson MH","year":"1999","unstructured":"Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. ArchInternMed. 1999 13 Sep;159(16):1893\u20131900.","journal-title":"ArchInternMed"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.4065\/76.10.971"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1317"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013501804"},{"issue":"6","key":"e_1_3_3_33_1","first-page":"467","article-title":"Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia","volume":"24","author":"Davidson MH","year":"2001","unstructured":"Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. ClinCardiol. 2001 6;24(6):467\u2013474.","journal-title":"ClinCardiol"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(01)00437-3"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00638-6"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.116004"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.11.022"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.11.039"},{"issue":"12","key":"e_1_3_3_39_1","first-page":"766","article-title":"Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use","volume":"11","author":"Reddy KJ","year":"2009","unstructured":"Reddy KJ, Singh M, Batsell RR, et al. Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use. J ClinHypertens(Greenwich). 2009 12;11(12):766\u2013768.","journal-title":"J ClinHypertens(Greenwich)"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.06.008"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2006.08.013"},{"issue":"11","key":"e_1_3_3_42_1","first-page":"2191","article-title":"Lipid-lowering effects of colesevelam HCl in combination with ezetimibe","volume":"22","author":"Bays H","year":"2006","unstructured":"Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. CurrMedResOpin. 2006 11;22(11):2191\u20132200.","journal-title":"CurrMedResOpin"},{"issue":"1","key":"e_1_3_3_43_1","first-page":"11","article-title":"Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance","volume":"13","author":"Rivers SM","year":"2007","unstructured":"Rivers SM, Kane MP, Busch RS, et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. EndocrPract. 2007 1;13(1):11\u201316.","journal-title":"EndocrPract"},{"issue":"9","key":"e_1_3_3_44_1","first-page":"1403","article-title":"Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia","volume":"21","author":"McKenney J","year":"2005","unstructured":"McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. CurrMedResOpin. 2005 9;21(9):1403\u20131412.","journal-title":"CurrMedResOpin"},{"issue":"4","key":"e_1_3_3_45_1","first-page":"615","article-title":"Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial","volume":"32","author":"Huijgen R","year":"2010","unstructured":"Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. ClinTher. 2010 4;32(4):615\u2013625.","journal-title":"ClinTher"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2007.09.001"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.s12187398"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30155-3"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000178994.21828.a7"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-S355"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23408"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-0965"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2014.04.016"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.11.1901"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00238.2018"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665116002834"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0923"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12648"},{"issue":"1","key":"e_1_3_3_59_1","first-page":"74","article-title":"Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes","volume":"29","author":"Zieve FJ","year":"2007","unstructured":"Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. ClinTher. 2007 1;29(1):74\u201383.","journal-title":"ClinTher"},{"issue":"18","key":"e_1_3_3_60_1","first-page":"1975","article-title":"Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects","volume":"168","author":"Bays HE","year":"2008","unstructured":"Bays HE, Goldberg RB, Truitt KE, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. ArchInternMed. 2008 Oct 13;168(18):1975\u20131983.","journal-title":"ArchInternMed"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0283"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1383648"},{"issue":"1","key":"e_1_3_3_63_1","first-page":"53","article-title":"Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy","volume":"16","author":"Rigby SP","year":"2010","unstructured":"Rigby SP, Handelsman Y, Lai YL, et al. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. EndocrPract. 2010 1;16(1):53\u201363.","journal-title":"EndocrPract"},{"issue":"14","key":"e_1_3_3_64_1","first-page":"1531","article-title":"Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy","volume":"168","author":"Goldberg RB","year":"2008","unstructured":"Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. ArchInternMed. 2008 28 Jul;168(14):1531\u20131540.","journal-title":"ArchInternMed"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP10130.OR"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1089\/met.2009.0049"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2382-3"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01486.x"},{"issue":"5","key":"e_1_3_3_69_1","first-page":"348","article-title":"The glucose and lipid effects of colesevelam as monotherapy in drug-naive type 2 diabetes","volume":"46","author":"Rosenstock J","year":"2014","unstructured":"Rosenstock J, Rigby SP, Ford DM, et al. The glucose and lipid effects of colesevelam as monotherapy in drug-naive type 2 diabetes. Horm Metab Res. 2014 May;46(5):348\u2013353.","journal-title":"Horm Metab Res"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2017.01.011"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01320.x"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14084"},{"issue":"25","key":"e_1_3_3_73_1","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"139","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2018 2019 Jun 18;139(25):e1082\u2013e1143.","journal-title":"Circulation"},{"issue":"32","key":"e_1_3_3_74_1","first-page":"2700","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"40","author":"Mach F","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, et al. ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019 Aug 31;40(32):2700\u20132709.","journal-title":"Eur Heart J"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1095"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1975.03240160024021"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300955"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.07.011"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60656-3"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001282"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0916-z"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31357-5"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011581"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30396-5"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30313-3"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X89766"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1809"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.09.010"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101124"},{"issue":"11","key":"e_1_3_3_91_1","first-page":"2549","article-title":"Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire","volume":"31","author":"Wedlake L","year":"2009","unstructured":"Wedlake L, Thomas K, Lalji A, et al. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. ClinTher. 2009 11;31(11):2549\u20132558.","journal-title":"ClinTher"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(03)00105-3"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044711"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2022.2112945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:28:08Z","timestamp":1772767688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2022.2112945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":91,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,8,13]]}},"alternative-id":["10.1080\/14656566.2022.2112945"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2022.2112945","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}